Utility of Genome-Wide Association Study findings: Prostate cancer as a translational research paradigm

Journal of Internal Medicine

Volumn 271, Issue 4, 2012, Pages 344-352

  Turner, A R ^a   Kader, A K ^b   Xu, J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Gene polymorphism; Molecular medicine; Risk factors

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AREA UNDER THE CURVE; CANCER RESEARCH; CANCER RISK; EVIDENCE BASED PRACTICE; GENETIC ASSOCIATION; HUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ATTITUDE OF HEALTH PERSONNEL; COMMERCE; DATABASES AS TOPIC; ETHICS, MEDICAL; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; PUBLIC HEALTH; RESEARCH; RISK FACTORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84863338435     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02522.x     Document Type: Review

References (44)

1. Hindorff LA, Junkins HA, Hall PN, Mehta JP, Manolio TA. A catalog of published genome-wide association studies. Accessed 15 August 2011 at.
2. Easton DF, Eeles RA. Genome-wide association studies in cancer. Hum Mol Genet 2008; 17: R109-15.
3. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008; 359: 2143-53.
4. Zheng SL, Sun J, Wiklund F et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910-9.
5. Xu J, Sun J, Kader AK et al. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate 2009; 69: 1565-72.
6. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31: 33-6.
7. Wacholder S, Hartge P, Prentice R et al. Performance of common genetic variants in prevention of breast cancer. NEJM 2010; 362: 986-93.
8. Devilee P, Rookus MA. A tiny step closer to personalized risk prediction for breast cancer. NEJM 2010; 362: 1043-5.
9. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 159: 882-90.
10. Ioannidis JP. Personalized genetic prediction: too limited, too expensive, or too soon? Ann Intern Med 2009; 150: 139-41.
11. Kraft P, Hunter DJ. Genetic risk prediction - are we there yet? N Engl J Med 2009; 360: 1701-3.
12. Wiklund F. Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers? Genome Med 2010; 2: 45.
13. Penney KL, Pyne S, Schumacher FR et al. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2010; 19: 2869-76, Epub 2010 Oct 26.
14. Kader AK, Sun J, Isaacs SD et al. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5, 895 prostate cancer patients. Prostate 2009; 69: 1195-205.
15. Xu J, Zheng SL, Isaacs SD et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A 2010; 107: 2136-40, Epub 2010 Jan 11.
16. The Genetics and Public Policy Center. Accessed June 1, 2010 at Published May 28, 2010.
17. Javit G, Hudson K. Federal neglect: regulation of genetic testing. Issues Sci Technol 2006; Spring, 22: 59-66.
18. Secretary's Advisory Committee on Genetics, Health and Society. Accessed 30 April 2008 at.
19. FDA website. Accessed 20 August 2011 at and.
20. Feng J, Sun J, Kim ST et al. A genome-wide survey over the ChIP-on-chip identified androgen receptor-binding genomic regions identifies a novel prostate cancer susceptibility locus at 12q13.13. Cancer Epidemiol Biomarkers Prev 2011; 20: 2396-403.
21. Jakobsdottir J, Gorin MB, Conley YP, Ferrell RE, Weeks DE. Interpretation of genetic association studies: markers with replicated highly significant odds ratios may be poor classifiers. PLoS Genet 2009; 5: e1000337.
22. Sun J, Kader AK, Hsu FC et al. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate 2011; 71: 421-30, Epub 2010 Sep 28.
23. FitzGerald LM, Kwon EM, Conomos MP et al. Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 1196.
24. Pomerantz MM, Werner L, Xie W et al. Association of prostate cancer risk loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res 2011; 4: 719.
25. Gallagher DJ, Vijai J, Cronin AM et al. Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res 2010; 16: 2819.
26. Wiklund F. Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate 2009; 69: 419-27.
27. Ahn J et al. Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet 2008; 40: 1032-4.
28. Gudmundsson J et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2010; 2: 62ra92.
29. Andriole GA, Bostwick D, Brawley OW. The influence of dutasteride on the risk of biopsy-detectable prostate cancer: outcomes of the REduction by DUtasteride of Prostate Cancer Events (REDUCE) study. N Engl J Med 2010; 362: 1192-202.
30. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride in the development of prostate cancer. N Engl J Med 2003; 349: 215-24.
31. Aly M, Wiklund F, Xu J et al. polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur. Urol. 2011; 60: e1-8.
32. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 2007; 9: 665-74. Review.
33. Woolf SH. The meaning of translational research and why it matters. JAMA 2008; 299: 211-3.
34. Lean M, Mann J, Hoek J, Elliot R, Schofield G. From evidence based medicine to sustainable solutions for public health problems. BMJ 2008; 337: a863.
35. NIH TRWG. Accessed 14 June 2010 at.
36. Hiss RG. Fundamental issues in translational research. Translational research-two phases of a continuum. In: From Clinical Trials to Community: the Science of Translating Diabetes and Obesity Research. Bethesda, MD, USA: Natcher Conference Center, National Institutes of Health, 2004:11-4. Accessed 08 January 2011 at.
37. Ioannidis JP. Materializing research promises: opportunities, priorities and conflicts in translational medicine. J Transl Med 2004; 2: 5.
38. Schully SD, Benedicto CB, Gillanders EM, Wang SS, Khoury MJ. Translational research in cancer genetics: the road less traveled. Public Health Genomics 2011; 14: 1-8.
39. Committee on Comparative Effectiveness Research Prioritization, Institute of Medicine (IOM). Initial National Priorities for Comparative Effectiveness Research. Washington, DC: The National Academies Press, 2009.
40. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010; 363: 301-4, Epub 2010 Jun 15.
41. Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study. Alzheimer Dis Assoc Disord 2008; 22: 94-7.
42. Green RC, Roberts JS, Cupples LA et al. Disclosure of APOE genotype for risk of Alzheimer's disease. NEJM 2009; 361: 245-54.
43. Sanderson SC, O'Neill SC, White DB et al. Responses to online GSTM1 genetic test results among smokers related to patients with lung cancer: a pilot study. Cancer Epidemiol Biomarkers Prev 2009; 18: 1953-61.
44. Stack CB, Gharani N, Gordon ES, Schmidlen T, Christman MF, Keller MA. Genetic risk estimation in the coriell personalized medicine collaborative. Genet Med 2011; 13: 131-9.